Biotech Startups

1 investor

Frezent develops next-generation antibody biologics that target both dividing and dormant cancer cells to eliminate minimal residual disease and prevent cancer recurrence. It applies AI tools to optimize its antibodies and integrates its treatment with standard of care in oncology.

1 investor

Frontage Laboratories is a contract research and development organization (CRO/CDMO) offering end-to-end drug discovery and development services, including DMPK, safety and toxicology, bioanalytical, CMC manufacturing, clinical, and central lab services. It serves pharmaceutical and agrochemical clients, supporting compounds from discovery through clinical trial manufacturing.

1 investor

Frontage is a contract research organization offering drug candidate evaluation services including screening, DMPK, drug safety assessment, and bioanalysis, along with formulation development and CMC services from discovery through post-approval. It also runs clinical research and a central laboratory providing lab testing, global logistics, and project management for pharmaceutical clients.

1 investor

Frontera Therapeutics is a biotechnology company engaged in therapeutic research and development, spanning translational medicine, clinical operations, and manufacturing.

1 investor

Frontier Space Technologies develops in-space R&D and biomanufacturing platforms that use the microgravity space environment to accelerate biotechnology work. The UK-based company aims to make the space environment more accessible for biotech applications benefiting life on Earth.

1 investor

A venture capital firm investing €1–6M in Seed to Series A companies at the intersection of life science and technology, covering digital health, medtech, and life science tools.

1 investor

VisualSonics develops ultra-high frequency ultrasound and photoacoustic imaging systems for preclinical research, enabling real-time visualization of anatomical, functional, and molecular data in small animals. The company serves biomedical researchers requiring non-invasive in vivo imaging for drug development and life sciences research.

1 investor

Fulmer Instruments develops a handheld, cordless battery-powered bipolar electrosurgical generator for tissue coagulation, intended for surgeons in hospitals, ambulatory surgery centers, and resource-limited settings. The company targets the surgical medical device market and is based in Alabama, USA.

1 investor

Fulmz offers an AI-powered platform for drug discovery that combines molecular design, large-scale screening, and computational optimization to accelerate the development of small molecule drugs. The platform serves pharmaceutical researchers and drug development organizations seeking to compress preclinical research timelines.

1 investor

FUNBRUSH develops an antifouling and antibacterial nanocoating for biosensors and bioanalytical platforms, enabling sensitive detection in complex, undiluted sample media such as blood plasma, food, and environmental samples. It targets applications in diagnostics, healthcare, food safety, security, and environmental monitoring, and is compatible with SPR, QCM, optical fiber, and electrochemical sensor platforms.

1 investor

FunCell develops BioGraft, a technology that adds functional properties like barrier capabilities to paper and cellulosic materials, enabling new applications in the packaging industry. The company provides chemistry expertise and industrial research services to innovate cellulose-based packaging solutions.

1 investor

Mission Bay Capital is an early-stage investment firm dedicated to funding and supporting entrepreneur-scientists building companies to address chronic diseases and environmental challenges. The firm provides capital, laboratory facilities through its incubator MBC BioLabs, and access to a network of advisors and industry partners.

1 investor

Fundació Villavecchia is a foundation that supports research, specialized training for medical professionals, and hospital improvements in the fight against childhood cancer. The organization funds research registries, awards fellowships and scholarships for pediatric oncology and hematology specialists, and collaborates with hospital centers to improve patient and family experiences.

1 investor

Unoentrecienmil is a Spanish research foundation that funds investigative projects focused on finding a cure for childhood leukemia through annual research grants.

1 investor

FungiFix uses mycoremediation to remove contaminants from polluted soil, then transforms the fungal biomass into sustainable biofillers for concrete. The company targets contaminated land remediation in states like California, combining environmental restoration with sustainable construction materials.

1 investor

FungiLife produces high-performance sophorolipids, a fungal biosurfactant made through a scalable liquid-state fermentation process using a proprietary fungus. It supplies 100% biodegradable biosurfactants to industries including oil and gas, industrial and home cleaning, cosmetics, agriculture, and bioremediation.

1 investor

Fungit develops microorganism-based biocontrol agents, using fungal microorganisms to extend the shelf life of fruits and vegetables and protect crops in pre-harvest and post-harvest agriculture. It serves growers and packagers as an alternative to chemical fertilizers and pesticides, and is based in Israel.

1 investor

Fuse Vectors develops AAV manufacturing platforms for biotech researchers and developers, enabling efficient production from early discovery screening through preclinical validation to clinical-grade manufacturing.

1 investor

Fusion Antibodies optimizes antibody development for research and therapeutic applications. The company serves pharmaceutical and biotech customers seeking to enhance antibody performance.

1 investor

Futura Genomics provides accredited genetic testing services that deliver personalized health and ancestry insights tailored to diverse populations, with particular focus on African heritage. The company partners customers with medical professionals and wellness specialists to translate genetic data into actionable health recommendations.

1 investor

FuturedMe develops small-molecule drug candidates using CANDDY, a protein-degradation platform licensed from Tokyo University of Science that induces direct proteasomal degradation of disease-related proteins instead of inhibiting them. The company aims to create therapies for patients with previously undruggable targets and no existing treatment options.

1 investor

Fuzionaire develops chemistry technology based on Earth-abundant alkali metal catalysts and reagents (its ionic alkali metal / IAM platform) for applications in medicine, energy, and materials. The platform originated from discoveries at Caltech, UCLA, and other institutions and targets molecular-level innovation across pharmaceuticals, clean energy, and advanced materials.

1 investor

Fuzionaire Theranostics develops radiopharmaceuticals for oncology using its HetSiFA silicon (SiFA) chemistry platform, creating chemically matched fluorine-18 PET diagnostic and radioligand therapy pairs. Its lead program, FTX-426, targets GRPR-expressing solid tumors such as prostate and breast cancer.

1 investor